Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.

scientific article published on February 1999

Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S0168-8278(99)80061-0
P698PubMed publication ID10068095

P50authorBettina HansenQ40007319
P2093author name stringJ T Brouwer
S W Schalm
H G Niesters
P2860cites workComparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approachQ29614698
Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.Q36865888
Factors predictive of a beneficial response to therapy of hepatitis C.Q40882250
Measuring hepatitis C viremia in clinical samples: Can we trust the assays?Q41523834
Therapy of hepatitis C: overviewQ41598802
A French consensus conference on hepatitis C: screening and treatmentQ41651187
International collaborative study on the second EUROHEP HCV-RNA reference panelQ42978378
Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparisonQ42985824
Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study GroupQ42986315
Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfaQ42987319
Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patientsQ42989126
Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapyQ42989131
A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study GroupQ43039883
Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter studyQ43048305
Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study GroupQ70955349
Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and durationQ71650797
National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis CQ73717356
P433issue2
P921main subjectribavirinQ421862
chronic hepatitis CQ55779873
P304page(s)192-198
P577publication date1999-02-01
P1433published inJournal of HepatologyQ15724402
P1476titleEarly prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.
P478volume30